ReviewInternational journal of hematology2026
Donor selection for allogeneic hematopoietic cell transplantation in the posttransplant cyclophosphamide era.
Review in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The adoption of posttransplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis has reduced non-relapse mortality in allogeneic hematopoietic cell transplantation (allo-HCT) by overcoming the barrier of HLA disparity. Allo-HCT from an HLA-haploidentical-related donor with PTCy (PTCy-haplo) has become a feasible allo-HCT platform. Even in the PTCy era, allo-HCT from an HLA-matched related donor (MRD) has achieved the highest overall survival. However, the optimal donor choice when an MRD is unavailable remains a subject of debate. We discuss outcomes of PTCy-haplo compared with alternative donor sources, such as HLA-matched unrelated donors, HLA-mismatched unrelated donors, and cord blood, and propose a provisional donor selection matrix that combines HLA matching with clinical urgency. In clinical practice, even when multiple donor candidates are available, it is rare to find one with all favorable prognostic factors, including donor age, CD34
Indexed as
Identifiers
41973297What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.